Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of JS1-1-01 tablets for moderate to severe major depressive disorder
CTR20233894Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS1-1, duloxetine in major depressive disorder (MDD), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Dec 2023; status: completed.
02
Drugs
JS1-1duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20233894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233894.